Friday, May 1, 2026

#rare diseases

2 articles

U.S. Rare Disease Drugmaker Faces $200M Revenue Loss as Patent Cliff Looms in 2035

Healthcare & Pharmaceuticals

U.S. Rare Disease Drugmaker Faces $200M Revenue Loss as Patent Cliff Looms in 2035

ViaNews Editorial Team•Mar 12, 2026

Zevra Therapeutics risks collapse as 90% revenue depends on single rare disease drug

Zevra Therapeutics risks collapse as 90% revenue depends on single rare disease drug

ViaNews Editorial Team•Feb 25, 2026